Allarity Therapeutics (NASDAQ:ALLR) Releases FY 2026 Earnings Guidance

Allarity Therapeutics (NASDAQ:ALLR) issued an update on its FY 2026 earnings guidance on Friday. The company provided EPS guidance of -0.760–0.730 for the period, compared to the consensus estimate of -0.800. Allarity Therapeutics also updated its Q4 2026 guidance to 0.010-0.040 EPS.

Allarity Therapeutics Stock Performance

NASDAQ:ALLR opened at $0.91 on Friday. The stock’s fifty day moving average price is $1.02 and its two-hundred day moving average price is $1.21. Allarity Therapeutics has a 52-week low of $0.77 and a 52-week high of $1.84. The company has a market cap of $14.54 million, a price-to-earnings ratio of -1.17 and a beta of 0.57.

Allarity Therapeutics (NASDAQ:ALLR) last released its earnings results on Friday, November 13th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.18). The firm had revenue of $0.01 million during the quarter. Allarity Therapeutics has set its FY 2026 guidance at -0.760–0.730 EPS and its Q4 2026 guidance at 0.010-0.040 EPS. On average, equities analysts predict that Allarity Therapeutics will post -0.80 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Allarity Therapeutics in a report on Thursday, October 15th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $10.25.

About Allarity Therapeutics

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biotechnology company focused on developing personalized treatments for cancer. The company uses its Drug Response Predictor (DRP) technology to analyze patient and tumor characteristics and identify individuals who may be more likely to respond to specific drug candidates. Allarity’s development programs have included stenoparib, also known as 2X-121, an orally administered PARP inhibitor being investigated for potential use in oncology.